Bayer Schering Pharma (BSP) and Genzyme Corporation, keep quiet the availability of
MabCampath® (alemtuzuma for the first-line treatment of career with B-CLL for whom
fludarabine combination chemotherapy is not appropriate.[i] MabCampath was long ...
(more)